Find scientific publication related to our products
We list information and link of the publication related to our products as below, you may have access to these publications through your emails or your institution's subscriptions to the database.
Aom0498 |
Qi Youmao, Jie Qing, Zhang Fengmin, Yu Baochun, Ding Ding, Qi Yingbei. Muscle relaxant effect of new γ-cyclodextrin derivatives Aom0498-1
and Aom0498-3. Chinese Journal of Pharmacology and Toxicology 26(6):787-793.
doi: 10.3867/j.issn.1000-3002.2012.06.002
Qi Youmao, Qi Yingbei, Yu Baochun, Lao Qiaocong, Li Chunqi, Zhu difeng, Jie Qing. Screened adamgammadex for reversing rocuronium-induced neuromuscular blockade with greater safety. Chinese Journal of Pharmacology and Toxicology 32(7):515-527.
doi:10.3867/j.issn.1000-3002.2018.07.002
YingYing Jiang, YuJun Zhang, ShunJu Xiang, WenLing Zhao, Jin Liu, WenSheng Zhang. Safety, tolerability, and pharmacokinetics of adamgammadex
sodium, a novel agent to reverse the action of rocuronium and vecuronium, in healthy volunteers. European Journal of Pharmaceutical Sciences.
2020; 141: 105-134.
doi: 10.1016/j.ejps.2019.105134
Yanhua Zhao, Sifan Chen, Xiaorong Huai, Zhangjie Yu, Youmiao Qi, Jie Qing, Weifeng Yu, Diansan Su. Efficiency and Safety of the Selective Relaxant
Binding Agent Adamgammadex Sodium for Reversing Rocuronium-Induced Deep Neuromuscular Block: A Single-Center, Open-Label, Dose-Finding,
and Phase IIa Study. Front Med (Lausanne). 2021; 8: 697395.
doi: 10.3389/fmed.2021.697395.
Yingying Jiang, Yujun Zhang, Zhaoqiong Zhu, Yidan Huang, Dachun Zhou, Jingchen Liu, Chaoyu Li, Xiangdong Chen, Dingxin Kang, Shoushi Wang,
Jin Liu, Bin Liu, Wensheng Zhang. Comparison of the Efficacy and Safety of Adamgammadex with Sugammadex for Reversal of Rocuronium-
Induced Neuromuscular Block: Results of a Phase II Clinical Trial. J Clin Med. 2022; 11(23):6951.
Ying Ying Jiang, Yu Jun Zhang, Zhao Qiong Zhu, Yi Dan Huang, Da Chun Zhou, Jing Chen Liu, Chao Yu Li, Jin Liu, Bin Liu, Wen Sheng Zhang.
Adamgammadex in patients to reverse a moderate rocuronium-induced neuromuscular block. Br J Clin Pharmacol. 2022; 88(8):3760-3770.
Lyn Q, Ye P, Zhang H, et al. Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health
Organization pharmacovigilance database. Br J Clin Pharmacol. 2023, 89(2): 449-457.
Yujun Zhang, Yingying Jiang, et.al. Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of
rocuronium-induced neuromuscular block. British Journal of Anaesthesia. Available online 29 November 2023.
|
|